If you’re one of the 8 million American women with osteoporosis, your doctor has probably talked to you about treatment options to slow the disease’s progression and keep your bones in tip-top shape.

Patients who experience adverse ocular effects with bisphosphonates have a notably higher risk for osteonecrosis than those who do not experience such events, a large cohort study shows.

DEAR DR. ROACH: I’m a 65-year-old, overweight white woman. I recently had a DEXA scan, and based on the results, my general physician prescribed Fosamax for osteopenia. The first dose created a ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving long-term glucocorticoids should use oral bisphosphonates to reduce the risk for bone loss ...

May 13, 2011— -- Many doctors are changing the prescribing length of a class of osteoporosis medication known as bisphosphonates after mounting evidence has linked long-term use of the medication ...

SEATTLE -- Risk of death was lower in the years after a bisphosphonate was started following a fracture rather than denosumab (Prolia), a target trial emulation found. In adults ages 50 and older who ...

An updated position statement on the management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer provides the latest evidence-based guidance, with an ...

Please provide your email address to receive an email when new articles are posted on . The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for ...

The American College of Physicians updated its 2017 guideline on pharmacologic treatment of osteoporosis or low bone mass to prevent fractures in adults. In a shift from previous recommendations, the ...